RU2017108432A3 - - Google Patents

Download PDF

Info

Publication number
RU2017108432A3
RU2017108432A3 RU2017108432A RU2017108432A RU2017108432A3 RU 2017108432 A3 RU2017108432 A3 RU 2017108432A3 RU 2017108432 A RU2017108432 A RU 2017108432A RU 2017108432 A RU2017108432 A RU 2017108432A RU 2017108432 A3 RU2017108432 A3 RU 2017108432A3
Authority
RU
Russia
Application number
RU2017108432A
Other languages
Russian (ru)
Other versions
RU2017108432A (ru
RU2699995C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed filed Critical
Publication of RU2017108432A publication Critical patent/RU2017108432A/ru
Publication of RU2017108432A3 publication Critical patent/RU2017108432A3/ru
Application granted granted Critical
Publication of RU2699995C2 publication Critical patent/RU2699995C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017108432A 2014-09-15 2015-09-15 Жидкая ингаляционная композиция, содержащая rpl 554 RU2699995C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1416274.7 2014-09-15
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GB1504662.6 2015-03-19
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Publications (3)

Publication Number Publication Date
RU2017108432A RU2017108432A (ru) 2018-10-17
RU2017108432A3 true RU2017108432A3 (cg-RX-API-DMAC7.html) 2019-04-01
RU2699995C2 RU2699995C2 (ru) 2019-09-12

Family

ID=54196992

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017108432A RU2699995C2 (ru) 2014-09-15 2015-09-15 Жидкая ингаляционная композиция, содержащая rpl 554

Country Status (27)

Country Link
US (2) US9956171B2 (cg-RX-API-DMAC7.html)
EP (3) EP3332767B1 (cg-RX-API-DMAC7.html)
JP (2) JP6860477B2 (cg-RX-API-DMAC7.html)
KR (1) KR102379309B1 (cg-RX-API-DMAC7.html)
CN (3) CN106794157B (cg-RX-API-DMAC7.html)
AU (3) AU2015316592B2 (cg-RX-API-DMAC7.html)
CA (1) CA2959943C (cg-RX-API-DMAC7.html)
CY (3) CY1120264T1 (cg-RX-API-DMAC7.html)
DK (3) DK3494962T3 (cg-RX-API-DMAC7.html)
ES (3) ES2875584T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249415B (cg-RX-API-DMAC7.html)
HR (3) HRP20180833T1 (cg-RX-API-DMAC7.html)
HU (3) HUE055527T2 (cg-RX-API-DMAC7.html)
IL (1) IL250895B (cg-RX-API-DMAC7.html)
LT (3) LT3332767T (cg-RX-API-DMAC7.html)
MX (1) MX2017003102A (cg-RX-API-DMAC7.html)
MY (1) MY196072A (cg-RX-API-DMAC7.html)
NO (1) NO3193835T3 (cg-RX-API-DMAC7.html)
PH (1) PH12017500479B1 (cg-RX-API-DMAC7.html)
PL (3) PL3332767T3 (cg-RX-API-DMAC7.html)
PT (3) PT3494962T (cg-RX-API-DMAC7.html)
RS (3) RS57227B1 (cg-RX-API-DMAC7.html)
RU (1) RU2699995C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201701854WA (cg-RX-API-DMAC7.html)
SI (3) SI3494962T1 (cg-RX-API-DMAC7.html)
SM (3) SMT201800242T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016042313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
MY196072A (en) * 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
JP6814754B2 (ja) 2015-07-24 2021-01-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Bace1阻害剤ペプチド
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
AU2021208129A1 (en) * 2020-01-15 2022-08-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of tricyclic PDE3/PDE4 dual inhibitor compound
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN119816295A (zh) * 2022-08-08 2025-04-11 维罗纳制药公司 液体药物组合物
CA3263546A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Plc公司 顆粒組成物
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)
US20250249006A1 (en) * 2024-02-05 2025-08-07 Verona Pharma Plc Treatment
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249007A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
ES2172217T3 (es) * 1997-10-09 2002-09-16 Schering Corp Suspensiones de furoato de mometasona para nebulizacion.
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
RU2440972C2 (ru) * 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
RU2580835C2 (ru) * 2010-06-22 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Алкалоидные производные на основе сложных аминоэфиров и композиции лекарственных средств, содержащие их
TWI516488B (zh) * 2010-08-09 2016-01-11 維羅納製藥Plc公司 嘧啶并[6,1-a]異喹啉-4-酮化合物之結晶型
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
WO2015137720A1 (ko) * 2014-03-11 2015-09-17 엘지전자 주식회사 무선 통신 시스템에서 장치 대 장치 단말의 디스커버리 신호 전송 방법 및 장치
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
MY196072A (en) * 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
NZ767296A (en) 2024-01-26
SI3193835T1 (en) 2018-06-29
PH12017500479A1 (en) 2017-07-31
SI3332767T1 (sl) 2019-07-31
ES2875584T3 (es) 2021-11-10
PH12017500479B1 (en) 2021-07-21
CN111249260B (zh) 2023-01-10
CN106794157B (zh) 2021-03-09
CA2959943A1 (en) 2016-03-24
HUE055527T2 (hu) 2021-12-28
JP6795574B2 (ja) 2020-12-02
EP3494962B1 (en) 2021-05-26
NZ729796A (en) 2024-01-26
JP2019069978A (ja) 2019-05-09
RU2017108432A (ru) 2018-10-17
JP6860477B2 (ja) 2021-04-14
LT3494962T (lt) 2021-07-26
HUE038433T2 (hu) 2018-10-29
EP3193835A1 (en) 2017-07-26
HRP20191122T1 (hr) 2019-09-20
AU2020203081A1 (en) 2020-05-28
ES2730810T3 (es) 2019-11-12
SMT201900340T1 (it) 2019-07-11
CN111249260A (zh) 2020-06-09
HRP20211035T1 (hr) 2021-09-17
MY196072A (en) 2023-03-13
PT3193835T (pt) 2018-03-27
WO2016042313A1 (en) 2016-03-24
CY1120264T1 (el) 2019-07-10
HRP20180833T1 (hr) 2018-06-29
SG11201701854WA (en) 2017-04-27
LT3332767T (lt) 2019-06-25
AU2018286571B2 (en) 2020-04-02
BR112017005050A2 (pt) 2018-01-23
NO3193835T3 (cg-RX-API-DMAC7.html) 2018-08-04
KR20170054406A (ko) 2017-05-17
MX2017003102A (es) 2017-06-14
PL3332767T3 (pl) 2019-10-31
LT3193835T (lt) 2018-06-11
AU2015316592A1 (en) 2017-03-23
AU2020203081B2 (en) 2021-08-05
KR102379309B1 (ko) 2022-03-28
RS62252B1 (sr) 2021-09-30
US20170239178A1 (en) 2017-08-24
US10945950B2 (en) 2021-03-16
PL3193835T3 (pl) 2018-07-31
HUE045303T2 (hu) 2019-12-30
IL250895B (en) 2019-08-29
SI3494962T1 (sl) 2021-09-30
SMT201800242T1 (it) 2018-07-17
CY1121698T1 (el) 2020-07-31
CN110051627A (zh) 2019-07-26
NZ767295A (en) 2024-01-26
CA2959943C (en) 2022-08-16
AU2018286571A1 (en) 2019-01-24
DK3494962T3 (da) 2021-06-21
SMT202100479T1 (it) 2021-09-14
PT3332767T (pt) 2019-06-27
CY1124546T1 (el) 2022-07-22
CN106794157A (zh) 2017-05-31
AU2015316592B2 (en) 2020-04-02
PT3494962T (pt) 2021-06-22
RS58897B1 (sr) 2019-08-30
EP3193835B1 (en) 2018-03-07
JP2017528479A (ja) 2017-09-28
EP3332767B1 (en) 2019-03-20
ES2670025T3 (es) 2018-05-29
PL3494962T3 (pl) 2021-12-06
HK1249415B (en) 2019-11-22
DK3332767T3 (da) 2019-06-24
US20180369139A1 (en) 2018-12-27
RU2699995C2 (ru) 2019-09-12
EP3494962A1 (en) 2019-06-12
IL250895A0 (en) 2017-04-30
RS57227B1 (sr) 2018-07-31
DK3193835T3 (en) 2018-05-07
EP3332767A1 (en) 2018-06-13
US9956171B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
BR112016016195A2 (cg-RX-API-DMAC7.html)
BR112016016951A2 (cg-RX-API-DMAC7.html)
BR112016017303A2 (cg-RX-API-DMAC7.html)
BR112016016741A2 (cg-RX-API-DMAC7.html)
BR112016018369A2 (cg-RX-API-DMAC7.html)
BR112016017657A2 (cg-RX-API-DMAC7.html)
BR112016016451A2 (cg-RX-API-DMAC7.html)
BR112016017137A2 (cg-RX-API-DMAC7.html)
BR112016016751A2 (cg-RX-API-DMAC7.html)
BR112016018705A2 (cg-RX-API-DMAC7.html)
BR112016016992A2 (cg-RX-API-DMAC7.html)
BR112016016268A2 (cg-RX-API-DMAC7.html)
BR112016016944A2 (cg-RX-API-DMAC7.html)
BR112016017216A2 (cg-RX-API-DMAC7.html)
BR112016016537A2 (cg-RX-API-DMAC7.html)
BR112016027471A2 (cg-RX-API-DMAC7.html)
BR112016017679A2 (cg-RX-API-DMAC7.html)
BR112016017130A2 (cg-RX-API-DMAC7.html)
BR112016018749A2 (cg-RX-API-DMAC7.html)
BR112016017542A2 (cg-RX-API-DMAC7.html)
BR112016017752A2 (cg-RX-API-DMAC7.html)
BR112016017513A2 (cg-RX-API-DMAC7.html)
BR112016017562A2 (cg-RX-API-DMAC7.html)
BR112016017981A2 (cg-RX-API-DMAC7.html)
BR112016017689A2 (cg-RX-API-DMAC7.html)